Presymptomatic late-onset Pompe disease: Optimizing the timing of treatment - 13/11/25
, C. Lefeuvre a, E. Berling a, A. Rouyer a, G. Nicolas a, P. Laforêt aAbstract |
Late-onset Pompe disease (LOPD) is a genetic myopathy causing severe limb girdle and diaphragmatic weakness. Pre-symptomatic diagnosis of LOPD is increasing. Enzyme replacement therapy (ERT) has shown dramatic efficacy in infantile-onset forms of the disease, supporting early diagnosis and treatment initiation, whereas the benefit of ERT on muscle weakness and respiratory insufficiency is moderate and not sustained over time in LOPD, raising questions about presymptomatic screening. Here, we present three presymptomatic cases of LOPD, showing that clinical symptoms can occur long after the diagnosis, resulting in a close monitoring without the need for treatment over several years. Several tests, such as walking tests, pulmonary function tests or whole-body muscle magnetic resonance imaging are sensitive for detecting early disease progression. Current guidelines provide no clear recommendations regarding the optimal timing of treatment initiation in presymptomatic patients. Nevertheless, in the context of a disease with a highly variable course, regular clinical, physiological and radiological assessments of each patient may allow for early detection of disease progression and support the decision to initiate treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Late-onset Pompe disease, Presymptomatic diagnosis, Muscle MRI, Enzyme replacement therapy
Plan
| ☆ | Given his role as a member of the Scientific Advisory Board, the author Pascal Laforêt was not involved in the peer-review process of this article, nor did he have access to any information regarding this process. He did not participate in the decision-making regarding the article. |
Vol 181 - N° 9
P. 922-928 - novembre 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
